Evidence map›Paper›PMID 30271455›Full record

ReviewEvidence-based complementary and alternative medicine : eCAM2018

Ozone Therapy as Adjuvant for Cancer Treatment: Is Further Research Warranted?

Bernardino Clavo, Norberto Santana-Rodríguez, Pedro Llontop, Dominga Gutiérrez, Gerardo Suárez, Laura López, Gloria Rovira, Gregorio Martínez-Sánchez, Esteban González, Ignacio J Jorge and 3 more

2 registry-linked trialsOpen access · hybridAbstract readReview
In one paragraph

Review in Evidence-based complementary and alternative medicine : eCAM, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 28 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 1 pooled it
4.2field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05417737 recruitingnot on this mapstarted 2022, after this paper: background citation

Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2022 and 2025. (EPOOzo)

Typeobservational_patient_registrySponsorBernardino Clavo, MD, PhDRan2022 to 2026Enrolled105ConditionsRadiation Toxicity, Chemotherapeutic Toxicity, Chemotherapy-induced Peripheral Neuropathy, Delayed Wound HealingArmsOzone therapy
NCT07325851 not yet recruitingnot on this mapstarted 2026, after this paper: background citation

Prospective and Observational Study of Patients Referred to the Chronic Pain Unit for Palliative Treatment With Ozone Therapy Between 2026 and 2029. Prospective Study EPOOzo-2.

Typeobservational_patient_registrySponsorBernardino Clavo, MD, PhDRan2026 to 2030Enrolled120ConditionsChemotherapy-Induced Peripheral Neuropathy, Radiation Toxicity, Chronic Pain, Delayed Wound HealingArmsOzone Therapy
3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 1 synthesis or guideline pooled it, 71 citations in OpenAlex.

  1. Systemic Review: Ozone: A Potential New Chemotherapy.International journal of molecular sciences · 2021
    Pooled it
  2. Trial
  3. Article
  4. Review
  5. Review
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Complementary and Alternative Therapies in Oncology.International journal of environmental research and public health · 2022
    Review
  15. Review
  16. Medical ozone induces proliferation and migration inhibition through ROS accumulation and PI3K/AKT/NF-κB suppression in human liver cancer cells in vitro.Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico · 2021
    Article
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 4 countries.

Bernardino ClavoResearch Unit, Dr. Negrín University Hospital, Las Palmas, Spain.ORCID 0000-0003-2522-1064
Norberto Santana-RodríguezInstituto Universitario de Investigaciones Biomédicas y Sanitarias (IUIBS), Grupo BIOPHARM, Universidad de Las Palmas de Gran Canaria, Las Palmas, Spain.
Pedro LlontopExperimental Medicine and Surgery Unit of Hospital Gregorio Marañón and the Health Research Institute of Hospital Gregorio Marañón (IiSGM), Madrid, Spain.
Dominga GutiérrezServicio Atención Especializada, Dirección General de Programas Asistenciales, Servicio Canario de Salud, Las Palmas, Spain.
Gerardo SuárezRadiation Oncology Department, Dr. Negrín University Hospital, Las Palmas, Spain.
Laura LópezRadiation Oncology Department, Dr. Negrín University Hospital, Las Palmas, Spain.
Gloria RoviraUnidad de Ozonoterapia, Hospital Quirónsalud, Barcelona, Spain.
Gregorio Martínez-SánchezUniversity of Saint George, Italy.
Esteban GonzálezClinicanaria Internacional, Las Palmas, Spain.
Ignacio J JorgeChronic Pain Unit of the Dr. Negrín University Hospital, Las Palmas, Spain.
Carmen PereraDepartment of Nuclear Medicine, DIMEC Center, Clínica San Roque, Las Palmas, Spain.
Jesús BlancoRadiation Oncology Department, Dr. Negrín University Hospital, Las Palmas, Spain.
Francisco Rodríguez-EsparragónResearch Unit, Dr. Negrín University Hospital, Las Palmas, Spain.ORCID 0000-0003-1663-3673
Galen University · BZUniversidad de Las Palmas de Gran Canaria · ESHospital General Universitario Gregorio Marañón · ESHospital Quirónsalud Barcelona · ESHospital Universitario de Gran Canaria Doctor Negrín · ESSaint George Hospital · LBServicio Canario de la Salud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionThis article provides an overview of the potential use of ozone as an adjuvant during cancer treatment.

methodsWe summarize the findings of the most relevant publications focused on this goal, and we include our related clinical experience.

resultsOver several decades, prestigious journals have published

conclusions

Identifiers

PMID30271455
PMCPMC6151231
OpenAlexW2891776080

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.